On May 20, 2020, Diffusion Pharmaceuticals announced it had entered into an agreement with the Romanian National Institute of Infectious Diseases (NIID) to begin a clinical trial program to test Diffusionﾒs lead drug trans sodium crocetinate for the treatment of hospitalized COVID-19 patients presenting with lowered blood oxygen levels, a condition known as hypoxemia.